You are here

Cell-based screening of combinatorial siRNA libraries

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM074436-01A1
Agency Tracking Number: GM074436
Amount: $337,512.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
CYNTELLECT, INC. 6620 Mesa Ridge Rd
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 450-7077
Business Contact
Phone: (858) 550-1770
Research Institution

DESCRIPTION (provided by applicant): RNA interference (RNAi) is a specific post-transcriptional gene silencing pathway mediated by intracellular dsRNAs of 21-23 bp in length known as small interfering RNA (siRNA). Since the recent discovery of effective siRNA-mediated gene silencing in mammalian cells, there has been significant validation and enormous interest in the approach from both academic and corporate researchers, for both discovery and therapeutic applications. Despite its great utility, the practice of RNAi would significantly benefit from (i) improved oligonucleotide chemistry for stability and efficacy at low concentrations to limit off-target effects, (ii) efficient and non-toxic delivery methods into cells, and (iii) lower cost siRNA reagents. This proposal describes an interdisciplinary effort between experienced groups to evaluate novel approaches to address these needs. A first-generation bead-based combinatorial thio-modified siRNA library will be generated and screened via cell-based high-throughput high-content screening (HT-HCS) using a novel HT cell imaging platform. Preliminary data within support the use of these oligonucleotide chemistries for RNAi applications and the HT-HCS capabilities needed to scale up to library screening efforts. Hits will be migrated to leads based on confirmatory screening and secondary assays. A focused second-generation combinatorial library will then be generated and screened based on first-generation results, again resulting in hits to be migrated to leads based on follow- up secondary assays. Results from these Phase I studies will be confirmed during Phase II studies which focus on additional target genes and cell lines, including influenza and host immunomodulatory genes with utility in infectious disease research and treatment. Success in this program will have broad impact in the field of RNAi and infectious diseases, resulting in more effective siRNA chemistries available with lower cost of production, HT-HCS cell-based screening methods for study of important models, and the potential for improved in vitro discovery and in vivo therapeutic RNAi approaches. siRNA represents an important new methodology that has led to new drug discovery research approaches, and holds significant promise for direct therapeutic applications. This proposal aims to improve the stability and utility of siRNA molecules and reduce their cost, thereby impacting the study and treatment potential for numerous diseases.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government